Good morning :)
Place Order
Add to Watchlist
Home
Portfolio
Search
GoldGold
More

Everest Organics Ltd

EVERESTO

Everest Organics Ltd

EVERESTO
Health CarePharmaceuticals
SmallcapWith a market cap of ₹94 cr, stock is ranked 3,062
High RiskStock is 3.64x as volatile as Nifty
118.553.62% (-4.45)
118.553.62% (-4.45)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹94 cr, stock is ranked 3,062
High RiskStock is 3.64x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹94 cr, stock is ranked 3,062
High RiskStock is 3.64x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
-15.832.07—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.276.550.51%

Forecast & Ratings

Detailed Forecast 
—
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Everest Organics Limited is a pharmaceutical company engaged in the business of bulk drugs, intermediates and active pharmaceutical ingredients (APIs).

Peers

Compare with peers 
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Price Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Revenue Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Earnings Per Share Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 4.85%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.07% to 0.05%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of -54.9%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue99.85107.87112.87156.39168.66182.63202.26189.98198.13188.01
Raw Materialssubtract61.7271.3272.9897.00103.52117.13141.72126.31124.64182.21
Power & Fuel Costsubtract7.429.5410.3410.8111.8512.3614.7018.8815.40
Employee Costsubtract7.228.749.3411.6413.3015.2616.3316.3018.80
Selling & Administrative Expensessubtract5.025.455.546.337.347.658.669.7510.52
Operating & Other expensessubtract12.915.846.8912.2411.926.3212.2110.8816.89
Depreciation/Amortizationsubtract2.732.452.682.843.213.373.804.475.805.97
Interest & Other Itemssubtract2.602.762.743.213.433.263.103.315.475.47
Taxes & Other Itemssubtract0.040.430.654.823.203.560.600.280.470.35
EPS0.302.372.149.3813.6117.151.42-0.250.17-7.49
DPS0.000.000.001.001.001.500.500.000.000.00
Payout ratio0.000.000.000.110.070.090.350.000.000.00
See Costs

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ cr

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2020

Annual report

PDF
FY 2021

Annual report

PDF

Investor Presentation

Jul 10PDF
FY 2022

Annual report

PDF
FY 2023

Annual report

PDF
FY 2024

Annual report

PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Valuation

Technical

Forecast

ScreenerCompare valuation on Screener

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Everest Organics Ltd677.432.07—
Sun Pharmaceutical Industries Ltd45.346.470.75%
Cipla Ltd31.214.800.82%
Torrent Pharmaceuticals Ltd65.3815.800.88%

Price Comparison

Compare EVERESTO with any stock or ETF
Compare EVERESTO with any stock or ETF
EVERESTO
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding74.15%0.00%0.05%0.00%25.80%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep0.00%0.00%0.00%0.00%0.00%0.00%

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 15, 2022

Final
Final | Div/Share: ₹0.50

Dividend/Share

₹0.50

Ex DateEx Date

Sep 15, 2022

Cash Dividend

Ex DateEx DateSep 8, 2021

Final
Final | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Sep 8, 2021

Cash Dividend

Ex DateEx DateFeb 17, 2021

Interim
Interim | Div/Share: ₹0.50

Dividend/Share

₹0.50

Ex DateEx Date

Feb 17, 2021

Cash Dividend

Ex DateEx DateSep 1, 2020

Final
Final | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Sep 1, 2020

Cash Dividend

Ex DateEx DateSep 3, 2019

Final
Final | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Sep 3, 2019

News & Opinions
Corporate
Everest Organics to convene AGM

Everest Organics announced that the Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Everest Organics to hold AGM

Everest Organics announced that the Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Everest Organics reports standalone net loss of Rs 6.09 crore in the June 2024 quarter

Net loss of Everest Organics reported to Rs 6.09 crore in the quarter ended June 2024 as against net profit of Rs 0.04 crore during the previous quarter ended June 2023. Sales declined 23.95% to Rs 32.45 crore in the quarter ended June 2024 as against Rs 42.67 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales32.4542.67 -24 OPM %-11.285.91 - PBDT-4.621.45 PL PBT-6.090.16 PL NP-6.090.04 PL Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Everest Organics to table results

Everest Organics will hold a meeting of the Board of Directors of the Company on 13 August 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live

Everest Organics reports standalone net loss of Rs 1.34 crore in the September 2021 quarter

2 years agoBusiness Standard
Everest Organics Develops Molnupiravir API, Here We Discuss This Opp | Halftime Report | CNBC-TV18
3 years agoCNBC-TV18

COVID-19: Everest Organics starts making ingredient for Merck’s molnupiravir drug

3 years agoBusiness Today

India’s Everest Organics starts making ingredient for Merck’s Covid pill

3 years agoBusiness Standard

India’s Everest Organics starts making ingredient for Merck’s COVID-19 pill

3 years agoEconomic Times

Everest Organics ends 15% higher on development of Molnupiravir, a new API to treat Covid-19

3 years agoIndia Infoline